Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

. is a biotechnology company focused on the discovery, development and commercialization of novel, targeted therapeutics directed at addressing unmet medical needs in oncology. Our drug development programs target the MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic Myelogenous Leukemia, or CML. Our drug discovery activities are focused on a portfolio of other protein and enzyme targets that have been implicated in human cancers, including JAK2, RON, ALK, RAS and IKKe. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.

Merger Agreement with Eli Lilly and Company

On July 8, 2008, SGX Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation ("Lilly"), and REM Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Lilly ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub will merge with and into SGX (the "Merger"), with SGX continuing as the surviving corporation and a wholly-owned subsidiary of Lilly. As a result of the Merger, each share of SGX common stock issued and outstanding immediately prior to the effective time of the Merger (other than shares held by Lilly or Merger Sub or by stockholders of SGX who have validly exercised their appraisal rights under Delaware law) will be converted into the right to receive $3.00 in cash, without interest.

Pursuant to the terms of the Merger Agreement and as permitted under the applicable SGX equity plans, all of SGX's unvested stock options will vest prior to the effective time of the Merger. Any issued and outstanding stock options with an exercise price per share greater than or equal to $3.00 that are not exe
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Celsion Corporation (the "Company") (NASDAQ: ... from two institutional healthcare investors to purchase an aggregate ... in an at-the-market registered direct offering and a concurrent ... The Company entered into a definitive purchase agreement ... to sell an aggregate of 3,000,000 shares of its ...
(Date:5/28/2015)... McKinney, Texas (PRWEB) May 28, 2015 ... products for use in applications such as animal ... fat and oil reduction in wastewater treatment plants ... be attending the World Pork Expo, June 3-5 ... earlier this year in a Wall Street Journal ...
(Date:5/28/2015)... NORTH BRUNSWICK, N.J. , May 28, 2015 ... that PDS0101, a cancer immunotherapy treatment targeting HPV-16, ... patients.  Currently, pre-cervical cancer is ... could offer a simple and effective non-surgical alternative. ... body,s defense mechanisms (T-cells) to recognize, target, and ...
(Date:5/28/2015)... BEACH, Fla. , May 28, 2015 ... supporting the anti-cancer potential of its growth hormone-releasing hormone ... at the 2015 ASCO Annual Meeting. The data ... target for Biscayne,s anti-cancer GHRH blockers, is present on ... status. These findings suggest that GHRH antagonists could have ...
Breaking Biology Technology:Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3
... April 15, 2011 Carmell Therapeutics, a company that ... of injured tissues, has closed on a Series A ... facility and collect data for early clinical validation for ... was led by Harbor Light Capital Partners, a private ...
... Therapeutics, Inc. (Nasdaq: HALO ) today announced ... patients who receive their insulin treatment with a ... Halozyme,s rHuPH20 (recombinant human hyaluronidase) with the active ingredient ... of action. These preliminary results represent the first reported ...
... Promising new devices for mechanical circulatory support of ... research, will be revealed this week at the International ... Meeting and Scientific Sessions. An update from the Pumps ... presented during the Meeting in San Diego.  PumpKIN is ...
Cached Biology Technology:Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 2Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 3Halozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps 2Halozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps 3Halozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps 4Progress in the Development of Mechanical Circulatory Support Devices for Children to be Presented at International Heart and Lung Transplant Meeting 2Progress in the Development of Mechanical Circulatory Support Devices for Children to be Presented at International Heart and Lung Transplant Meeting 3
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... to tackle wheat,s worst enemy , Unlocking ancient rice ... in aphids, mouths, Reducing crop losses with cereals that ... better Indian varieties , Over 40 international research organisations ... will harness bioscience to improve food security in developing ...
... the physical process that creates that oh-so-alluring new car ... out, not particularly wholesome for sensitive satellite instruments, either. But ... to protect those instruments from its ill effects. ... car is its factory-fresh new car smell, a distinctive aroma ...
... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... that its Board of Directors has declared a special cash ... total.  The special cash dividend will be paid on December ... 2012.  The Board of Directors has determined ...
Cached Biology News:Major international push to maximize bioscience research to help world's poorest farmers 2Major international push to maximize bioscience research to help world's poorest farmers 3Major international push to maximize bioscience research to help world's poorest farmers 4Ah, that new car smell: NASA technology protects spacecraft from outgassed molecular contaminants 2Ah, that new car smell: NASA technology protects spacecraft from outgassed molecular contaminants 3Aware, Inc. Declares Special Cash Dividend of $1.80 Per Share, or Approximately $40 Million in Total 2
... anti-Human Alpha 1 Acid Glycoprotein ... Goats were immunized with ... in Freund's adjuvant. The ... to ensure specificity. For ...
...
... Development kit contains the basic components required ... measure natural and recombinant canine Monocyte Chemotactic ... and serum.1 Each kit contains sufficient materials ... plates, provided that the following conditions are ...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Biology Products: